Q2 2024 · 13F-HR
Nan Fung Group Holdings Ltdholdings as filed
Filed 2024-08-13 · accession 0001012975-24-000323
$93.7M
Reported value
44
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 452327109 | ILMN | ILLUMINA INC | $12.4M | 13.3% | 119,196 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $11.1M | 11.9% | 368,665 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $7.1M | 7.58% | 120,038 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $5.8M | 6.21% | 1,373,550 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $5.2M | 5.56% | 436,378 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $4.5M | 4.79% | 74,022 | Common | SOLE |
| 30223G102 | EXAIEUR | EXSCIENTIA PLC | $4.4M | 4.68% | 859,892 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $4.2M | 4.44% | 106,680 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $3.9M | 4.17% | 144,570 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $3.6M | 3.87% | 106,100 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $3.3M | 3.56% | 1,883,179 | Common | SOLE |
| 07725L102 | ONC | BEIGENE LTD | $3.3M | 3.50% | 23,022 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $2.6M | 2.76% | 219,277 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $2.0M | 2.15% | 49,120 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $1.9M | 2.01% | 146,800 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $1.9M | 2.00% | 493,584 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $1.9M | 1.98% | 13,600 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $1.8M | 1.97% | 204,939 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $1.7M | 1.79% | 102,984 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $1.6M | 1.70% | 5,682 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $1.4M | 1.54% | 64,200 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $953,150 | 1.02% | 55,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $890,399 | 0.95% | 10,815 | Common | SOLE |
| 097702104 | BOLT1EUR | BOLT BIOTHERAPEUTICS INC | $875,214 | 0.93% | 1,166,952 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $699,419 | 0.75% | 49,082 | Common | SOLE |
| 04746L104 | — | ATHIRA PHARMA INC | $477,000 | 0.51% | 180,000 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $376,049 | 0.40% | 274,488 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $352,682 | 0.38% | 47,150 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $350,152 | 0.37% | 17,300 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $343,208 | 0.37% | 32,470 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $324,619 | 0.35% | 10,875 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $305,340 | 0.33% | 19,866 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $283,313 | 0.30% | 7,300 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $280,642 | 0.30% | 7,450 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $252,959 | 0.27% | 41,950 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $228,758 | 0.24% | 6,750 | Common | SOLE |
| N01045207 | AFMDQ | AFFIMED N V | $202,996 | 0.22% | 37,247 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $182,434 | 0.19% | 15,700 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $180,000 | 0.19% | 40,000 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $150,874 | 0.16% | 50,971 | Common | SOLE |
| 23306J200 | — | DBV TECHNOLOGIES S A | $148,565 | 0.16% | 185,475 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $79,574 | 0.08% | 47,936 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $75,017 | 0.08% | 31,922 | Common | SOLE |
| 31572Q808 | FGENEUR | FIBROGEN INC | $55,417 | 0.06% | 62,106 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.